Vertex Pharmaceuticals
Open
$428.85
Prev. Close
$428.85
High
$428.85
Low
$428.15
Market Snapshot
$107.38B
27.2
-2.08
$11.02B
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals expects increased revenue despite cautious investor sentiment as it approaches its Q1 earnings release on May 4, signaling potential growth in the biotech sector.
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Recently from Cashu
Vertex Pharmaceuticals' Cystic Fibrosis Treatments ALYFTREK and TRIKAFTA Receive FDA Approval for Expanded Use
Vertex Pharmaceuticals has achieved a significant milestone with the U.S. FDA approving the expanded use of its cystic fibrosis treatments, ALYFTREK and TRIKAFTA. This regulatory approval broadens pat…
CNBC Cures: Advocating for Rare Disease Awareness and Support in Healthcare
Empowering Voices in Rare Disease Advocacy: CNBC Cares for the Overlooked In a remarkable push for change in the healthcare landscape, CNBC initiates "CNBC Cures," a comprehensive project focused on t…
Vertex Pharmaceuticals Celebrates Phase 3 Success in Kidney Disease Treatment Amid Market Fluctuations
Vertex Pharmaceuticals Advances in Kidney Disease Therapy Amid Market Volatility Vertex Pharmaceuticals has achieved a significant milestone by successfully completing a Phase 3 trial for povetacicept…
Vertex Pharmaceuticals: Strategic Expansion in Kidney Disease Therapy Following Promising Pivetacicept Trial Results
Vertex Pharmaceuticals Positions Itself for Expansion in Kidney Disease Therapy Vertex Pharmaceuticals Inc. is making significant strides in expanding its therapeutic portfolio, most recently through…